Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026

Biofrontera Inc.

Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.
Net loss $4.8M ($0.41/shr) vs $4.2M ($0.47/shr); operating loss improved to $4.3M from $4.5M.
Adjusted EBITDA -$3.6M vs -$4.4M; cash consumption near zero; cash $6.3M vs $1.8M Q1 2025.
FDA accepted sNDA for Ameluz PDT for superficial BCC; PDUFA target date Sept 28, 2026.
Positive Phase 3 AK results (primary endpoint met) and Phase 2b acne data (58% lesion reduction); regained Nasdaq compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.